An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder

GlaxoSmithKline0 sites372 target enrollmentNovember 4, 2002

Overview

A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)

Registry

clinicaltrials.gov

Start Date

November 4, 2002

End Date

September 30, 2003

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Responsible Party

Sponsor

•Patients with a primary diagnosis other than MDD.
•Patients with a history of schizophrenia, schizoaffective disorders, seizure disorders or bipolar affective disorder.
•Patients receiving formal psychotherapy or cognitive/behavioral therapy concurrently or in the 12 weeks prior to screening visit.
•Patient is actively suicidal.
•Patients who have a history of migraine headaches.

Hamilton Depression Rating Scale

Time Frame: 8 Weeks

Hamilton Depression Rating Scale Clinical Global Impression-Global Improvement Clinical Global Impression-Severity of Illness Hospital Anxiety and Depression Scale(8 Weeks)